|
業務類別
|
Biotechnology |
|
業務概覽
|
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform). |
| 公司地址
| 1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320 |
| 電話號碼
| +1 805 623-4211 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.atarabio.com |
| 員工數量
| 153 |
| Dr. AnhCo Nguyen, PhD |
President, Chief Executive Officer and Director |
美元 585.77K |
28/04/2025 |
| Ms. Yanina Grant-Huerta |
Chief Accounting Officer |
-- |
31/03/2025 |
|
|
| Dr. Carol G. Gallagher,Pharm.D. |
Lead Independent Director |
28/04/2025 |
| Mr. Matthew K. Fust |
Independent Director |
28/04/2025 |
| Mr. Gregory A. Ciongoli |
Independent Director |
28/04/2025 |
| Mr. William K. Heiden |
Independent Director |
28/04/2025 |
| Mr. Nachi Subramanian |
Independent Director |
15/05/2025 |
| Mr. James Huang |
Independent Director |
15/05/2025 |
| Dr. AnhCo Nguyen, PhD |
President, Chief Executive Officer and Director |
28/04/2025 |
|
|
|
|
